Global Genitourinary Drugs Market 2019-2023

Below are some of the key findings from the genitourinary drugs market analysis report

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from the report.

Get a FREE sample now!

Global Genitourinary Drugs Industry Overview

The high prevalence of genitourinary diseases is one of the critical reasons that will drive market growth. Bacterial infections or STDs can cause genitourinary disorders. It also includes various carcinomas such as ovarian cancer, cervical cancer, bladder cancer, and prostate cancer. Age-related ailments such as Alzheimer’s and disorders like diabetes, obesity, and multiple sclerosis are significantly responsible for these conditions. Additionally, there is also a growing incidence of incontinence and interstitial cystitis. This will increase the consumption of these drugs, in turn, driving the genitourinary drugs market size.

Moreover, the advent of biologics and gene therapy will be one of the major trends that will gain traction in the global market. With the unavailability of curable treatments for some of the genitourinary diseases, companies are focusing on introducing novel treatment options such as gene therapy and biological therapies with minimal side-effects. These therapies treat conditions such as polyneuropathy of hereditary transthyretin-mediated amyloidosis. Physicians recommend biologics for the treatment of patients with multiple genitourinary diseases. The emergent of gene therapy and biologics, coupled with the growing prevalence of these diseases will drive genitourinary drugs market growth at a CAGR of almost 3% during the forecast period.

Top companies covered in the genitourinary drugs market research report

The genitourinary drugs market is moderately fragmented. By offering a complete analysis of the market’s competitive landscape and with information on the products offered by companies, the industry analysis report will help clients identify new growth opportunities and design innovative strategies to improve their market share.

The report offers a complete analysis of various companies including:

• Astellas Pharma Inc.
• AstraZeneca
• Eli Lilly and Company
• Johnson & Johnson Services, Inc.
• Novartis AG

Genitourinary drugs market segmentation based on geographic regions

• Asia
• Europe
• North America
• ROW

North America will account for the highest market share throughout the forecast period. The increased genitourinary diseases, increasing prevalence of STDs, the rise in geriatric population, and new research activities to develop treatment methods are significant factors for the high growth of the genitourinary drugs market in the region.

Genitourinary drugs market segmentation based on the type

• Genital diseases
• Urinary diseases

The genital diseases segment will account for the highest genitourinary drugs market share because of the growing prevalence of genital diseases such as primary and secondary syphilis cases and considered as the first choice of treatment for many genital diseases. The report provides an accurate prediction of the contribution of all the segments to the growth of the genitourinary drugs market size.

Key highlights of the global genitourinary drugs market for the forecast years 2019-2023:

• CAGR of the market during the forecast period 2019-2023
• Detailed information on factors that will accelerate the growth of the genitourinary drugs market during the next five years
• Precise estimation of the global genitourinary drugs market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the industry across various geographies such as Asia, Europe, North America, and ROW
• A thorough analysis of the market’s competitive landscape and detailed information on several vendors
• Comprehensive details on factors that will challenge the growth of drugs companies

We can help! Our analysts can customize the market research report to meet your requirements. Get in touch